Please use this identifier to cite or link to this item:
|Title:||Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.|
Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tibbi Onkoloji Bilim Dalı.
|Publisher:||Taylor & Francis|
|Citation:||Demiray, M. vd. (2006). ''Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study''. Cancer Investigation, 24(7), 669-676.|
|Abstract:||The M30-monoclonal antibody recognizes a neo-epitope of cytokeratin 18 which is formed after caspase-cleavage during apoptosis. Caspase-cleaved cytokeratin 18 is released from apoptotic cells into circulation. The aim of this study was to evaluate the relationship between M30-antigen level and chemotherapy response in neoadjuvant treatment of breast cancer. Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy. Serum samples were obtained for assessment of M30-antigen levels before the administration of first chemotherapy cycle (baseline), and then after 24 and 48 hours for determination of chemotherapy induced apoptosis. M30-antigen levels at 24 and 48 hours were found to be significantly higher than baseline (p < 0.001, p = 0.003, respectively). M30-antigen levels in responders showed statistically significant increases at 24 and 48 hours (p < 0.001; p = 0.004, respectively), while statistically significant increases were not observed in nonresponders. Percentage change of M30-antigen levels was significantly higher in responders than nonresponders at 24 hours (p = 0.020). In conclusion, our study revealed a significant relationship between increases of M30-antigen levels in serum and overall response to therapy.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.